SMSPHARMA Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
SMS Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹241.15 |
| 52 Week High | ₹398.00 |
| 52 Week Low | ₹113.30 |
| Beta | 1.29 |
| 11 Month Change | -19.68% |
| 3 Month Change | -32.43% |
| 1 Year Change | 96.78% |
| 33 Year Change | 85.07% |
| 5 Year Change | 507.43% |
| Change since IPO | 571.26% |
Recent News & Updates
Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Shareholder Returns
| SMSPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -8.4% | -0.5% | -1.2% |
| 1Y | 96.8% | 41.6% | 25.5% |
Return vs Industry: SMSPHARMA exceeded the Indian Pharmaceuticals industry which returned 41.6% over the past year.
Return vs Market: SMSPHARMA exceeded the Indian Market which returned 25.5% over the past year.
Price Volatility
| SMSPHARMA volatility | |
|---|---|
| SMSPHARMA Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SMSPHARMA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: SMSPHARMA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,197 | Ramesh Potluri | smspharma.com |
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. The company offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides.
SMS Pharmaceuticals Limited Fundamentals Summary
| SMSPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹20.41b |
| Earnings (TTM) | ₹593.38m |
| Revenue (TTM) | ₹7.68b |
34.4x
P/E Ratio2.7x
P/S RatioIs SMSPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMSPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹7.68b |
| Cost of Revenue | ₹5.38b |
| Gross Profit | ₹2.31b |
| Other Expenses | ₹1.71b |
| Earnings | ₹593.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.01 |
| Gross Margin | 30.02% |
| Net Profit Margin | 7.72% |
| Debt/Equity Ratio | 50.6% |
How did SMSPHARMA perform over the long term?
See historical performance and comparison